First-Ever Therapy to Delay Type 1 Diabetes Emerges

The U.S. Food and Drug Administration (FDA) has granted approval to Tzield (teplizumab-mzwv), developed by Provention Bio, which was acquired by Sanofi, as the first therapy to delay the onset of Type 1 Diabetes (T1D). Tzield is a CD3-targeted monoclonal antibody that modulates the immune system to suppress T cells that attack pancreatic beta cells. While existing treatments primarily focus on managing symptoms in patients already diagnosed with T1D, Tzield represents a paradigm shift by aiming to prevent or delay the onset of the disease through early screening. The drug successfully navigated the regulatory process, receiving a 10-7 recommendation for approval from its advisory committee, marking a significant milestone in the highly unmet need of autoimmune diseases.

Pivotal TN-10 Trial Demonstrates 2-Year Delay

The approval is based on the pivotal Phase 2 TN-10 trial, which involved 76 participants at high risk of developing T1D. The results showed that Tzield delayed the onset of symptomatic T1D by a median of 25 months compared to placebo (median of 50 months in the Tzield group versus 25 months in the placebo group). This translates to a 59% reduction in the risk of disease progression, with a hazard ratio of 0.41 (p-value 0.0066). This significant finding has the potential to dramatically improve the quality of life for patients and their families, who currently require daily insulin injections.

High Price Tag and Market Access Challenges

Sanofi has priced Tzield at $193,900 for a 14-day treatment course, based on the Wholesale Acquisition Cost (WAC), which has raised concerns about market access. Given the high price per vial, there are concerns that initial uptake may be limited by reimbursement challenges and restricted prescribing. However, Sanofi is implementing a copay program to reduce out-of-pocket costs for eligible patients, aiming to ensure broader access. Despite the high price, the company argues that Tzield offers long-term economic benefits by reducing the need for lifelong insulin therapy and monitoring, which could improve its chances of securing favorable reimbursement agreements with insurers.

Sanofi's Acquisition of Provention Bio and Synergistic Effects

Recognizing the commercial potential of Tzield, Sanofi completed the acquisition of Provention Bio in April 2023 for $25 per share, totaling $2.9 billion in cash. This acquisition builds upon a previous co-promotion agreement signed in October 2022, which included an upfront payment of $20 million. The acquisition demonstrates Sanofi's commitment to strengthening its immunology portfolio. With the T1D market projected to exceed $16 billion by 2026, Sanofi's strong global marketing infrastructure is expected to accelerate the commercial success of Tzield. This M&A deal is considered a successful model of collaboration between a biotech company with innovative assets and a large pharmaceutical company with global commercial capabilities.

Securing a Leading Position in a Competitive Landscape

Currently, Tzield holds a unique position in the global T1D delay treatment market as the only approved disease-modifying therapy (DMT). While Diamyd Medical's Diamyd is in Phase 3 clinical trials and Vertex Pharmaceuticals is developing a stem cell-based therapy, Tzield is the first to market. The company has also recently expanded the age range for treatment to include children as young as one year old, further expanding the potential patient population. As early screening becomes more widespread, Tzield's market dominance is expected to strengthen further.